Development of 36 clones producing human monoclonal antibodies specific to cancer cells and their ability to inhibit cancer cell growth

Anticancer Research

Volumn 28, Issue 3 A, 2008, Pages 1651-1657

  Nakamura, Rieko ^a   Saikawa, Yoshiro ^a   Hosokawa, Saiko ^b   Fukuda, Kazumasa ^a   Kumai, Koichiro ^a   Kubota, Tetsuro ^a   Kitajima, Masaki ^a   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY   (Japan)

^b MITSUBISHI CHEMICAL CORPORATION   (Japan)

Author keywords

Growth inhibition; Human monoclonal antibody; Hybridoma; Specificity to cancer cell

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; QUANTUM DOT; STREPTAVIDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CELL CLONE; CELL PROLIFERATION; CONTROLLED STUDY; FLUORESCENCE MICROSCOPE; HUMAN; HUMAN CELL; HYBRIDOMA; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; IMMUNIZATION, PASSIVE; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS;

EID: 45949088367     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Waldmann TA and Morris JC: Development of antibodies and chimeric molecules for cancer immunotherapy. Adv Immunol 90: 83-131, 2006.
2. Köhler G and Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497, 1975.
3. Nahta R and Estava FJ: HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 9: 5078-5084, 2003.
4. Thomas SM and Grandis JR: Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 30: 255-268, 2004.
5. Ferrara N: Vascular endothelial growth facter: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
6. Weiner LM: An overview of monoclonal antibody therapy of cancer. Semin Oncol 26: 41-50, 1999.
7. Harris M: Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5: 292-302, 2005.
8. Dybdal N, Leiberman G, Anderson S, McCune B, Bajamonde A, Cohen RL, Mass RD, Sanders C and Press MF: Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 93: 3-11, 2005.
9. Cobleigh M, Vogel C, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ: Multinational study of the efficacy and safety of humanised anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastastic breast cancer that has progressed after chemotherapy for metastastic disease. I Clin Oncol 17: 2639-2648, 1999.
10. Hainsworth J: Monoconal antibody therapy in lymphoid malignancies. Oncologist 5: 376-384, 2000.
11. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D and Dallaire BK: IDEC-C2B8 rituximab chimeric anti-CD20 monoclonal antibody therapy for replapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998.
12. Senba T, Kuroki M, Arakawa F, Yamamoto T, Kuwahara M, Haruno M and Ikeda S: Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model. Anticancer Res 18: 17-24, 1998.
13. Matsuoka Y, Matsuo Y, Okamoto N, Kuroki M, Kuroki M and Ikehara Y: Highly effective extraction of carcinoembryonic antigen with phosphatidylinositol- specific phospholipase C. Tumor Biol 12: 91-98, 1991.
14. Kuroki M, Kuroki M, Koga Y and Matsuoka Y: Monoclonal antibodies to carcinoembryonic antigen: a systematic analysis of antibody specificities by using related normal antigens and evidence for allotypic determination on carcinoembryonic antigen. J Immunol 133: 2090-2097, 1984.
15. Vose BM and Moore M: Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol 22: 27-40, 1985.
16. Shimokawara I, Imamura M, Yamanaka N, Ishii Y and Kikuchi K: Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: an immunoperoxidase study with anti-human T and B cell sera. Cancer 49: 1456-1464, 1982.
17. Allen C and Hogg N: Elevation of infiltrating mononuclear phagocytes in human colorectal tumors. J Natl Cancer Inst 78: 465-470, 1987.
18. Mantovani A: Tumor-associated macrophages. Curr Opin Immunol 2: 689-692, 1990.
19. Tahara H, Fujio K, Araki Y, Setoguchi K, Misaki Y, Kitamura T and Yamamoto K: Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte. J Immunol 171: 2154-2160, 2003.
20. Kass R, Bellone S, Palmieri M, Cane S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S and Santin AD: Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells. Breast Cancer Res Treat 80: 275-285, 2003.
21. Whiteside TL and Parmiani G: Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol Immunother 39: 15-21, 1994.
22. Vollmers HP, O'Conor R, Müller J and Kirchner T and Mülle-Hermelink HK: SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res 49: 2471-2476, 1989.
23. Pfaff M, O'Connor R, Vollmers HP and Müller-Hemelink HK: Human monoclonal antibody against a tissue polypeptide antigen-related protein from a patient with a signet-ring cell carcinoma of the stomach. Cancer Res 50: 5192-5198, 1990.
24. Vollmers, HP and Brändlein S: Nature's best weapons to fight cancer: reloading human monoclonal IgM antibodies. Hum Antibodies 11: 131-142, 2002.
25. Brändlein S, Phole T, Ruoff N, Wozniak E, Müller-Hermelink H and Vollmers P: Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res 63: 7995-8005, 2003.
26. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ and Ludwig DL: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63: 8912-8921, 2003.
27. Vollmers HP, Dammrich J, Ribbert H, Grassel S, Debus S, Heesemann J and Muller-Hemelink HK: Human monoclonal antibodies from stomach carcinoma patients react with Helicobacter pylori and stimulate stomach cancer cells in vitro. Cancer 74: 1525-1532, 1994.
28. Vollmers HP, Dammrich J, Ribbert H, Wozniak E and Muller-Hermelink HK: Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 76: 550-558, 1995.
29. Vollmers HP, Hensel F, Hermann R, Dammrich J, Wozniak E, Gessner P, Herrmann B, Zimmermann U and Muller-Hermelink HK: Tumor-specific apoptosis by the human monoclonal antibody SC-1: a new therapeutical approach for stomach cancer. Oncol Rep 5: 35-40, 1998.
30. Hensel F, Hermann R, Brandlein S, Krenn V, Schmausser B, Geis S, Muller-Hermelink HK and Vollmers HP: Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1- induced apoptosis. Lab Invest 81: 1553-1563, 2001.
31. Vollmers HP, Zimmermann U, Krenn V, Timmermann W, Illert B, Hensel F, Hermann R, Thiede A, Wilhelm M, Ruckle-Lanz H, Reindl L and Muller-Hermelink HK: Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol Rep 5: 549-552, 1998.
32. Hermann R, Hensel F, Muller EC, Keppler M, Souto-Carneiro M, Brandlein S, Muller-Hermelink HK and Vollmers HP: Deactivation of regulatory proteins hnRNP A1 and A2 during SC-1 induced apoptosis. Hum Antibodies 10: 83-90, 2001.
33. Hosokawa S, Tagawa T, Niki H, Hirakawa Y, Ito N, Nohga K and Nagaike K: Establishment and evaluation of cancer-specific human monoclonal antibody GAH for targeting chemotherapy using immunoliposomes. Hybridoma and Hybridomics 23: 109-120, 2004.
34. Hosokawa S, Tagawa T, Niki H, Hirakawa Y, Nohga K and Nagaike K: Efficacy of immunoliposomes on cancer models in a cell surface-antigen-density-dependent manner. Br J Cancer 89: 1545-1551, 2003.
35. Aoki M, Saikawa Y, Hosokawa S, Fukuda K, Kumai K, Kubota T, Otani Y and Kitajima M: A novel human monoclonal antibody derived from tumor infiltrating lymphocytes in lung cancer inhibits cancer cell growth with morphologic changes. Anticancer Res 25: 3791-3798, 2005.
36. Jain RK: Tumor physiology and antibody delivery. Front Radiat Ther Oncol 24: 32-46, 1990.
37. Liedert B, Pluim D, Schellens J and Thomale J: Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei, Nucleic Acids Res 34: e47,2006.